Profile data is unavailable for this security.
About the company
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.
- Revenue in USD (TTM)249.43m
- Net income in USD-55.29m
- Incorporated2021
- Employees497.00
- LocationImmunocore Holdings PLC90 Park Drive, Milton Park, AbingdonABINGDON OX14 4RYUnited KingdomGBR
- Phone+44 123 543 8600
- Websitehttp://www.immunocore.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.78bn | 160.00 | -- | 3.32 | -- | 458.18 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.79bn | 50.00 | -- | 5.33 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Arcellx Inc | 110.32m | -70.69m | 2.79bn | 130.00 | -- | 5.65 | -- | 25.32 | -1.49 | -1.49 | 2.30 | 9.28 | 0.1937 | -- | -- | 848,607.70 | -12.41 | -38.82 | -14.67 | -45.41 | -- | -- | -64.08 | -339.38 | -- | -- | 0.0749 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| ACADIA Pharmaceuticals Inc | 726.44m | -61.29m | 2.85bn | 597.00 | -- | 6.58 | -- | 3.92 | -0.3774 | -0.3774 | 4.43 | 2.62 | 1.09 | 1.96 | 9.05 | 1,216,812.00 | -9.17 | -27.50 | -12.81 | -32.73 | 94.27 | 95.62 | -8.44 | -38.35 | 2.28 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Merus NV | 43.95m | -154.94m | 2.86bn | 172.00 | -- | 7.91 | -- | 65.07 | -2.99 | -2.99 | 0.8519 | 6.16 | 0.1056 | -- | 13.56 | 255,505.80 | -37.24 | -29.35 | -45.30 | -35.36 | -- | -- | -352.56 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 2.95bn | 91.00 | -- | 6.64 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 3.05bn | 497.00 | -- | 8.23 | -- | 12.23 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Azenta Inc | 641.02m | -17.37m | 3.07bn | 3.50k | -- | 1.26 | 43.98 | 4.80 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.09bn | 517.00 | -- | 19.10 | -- | 7.73 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 3.10bn | 525.00 | -- | 16.75 | -- | 17.04 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 3.13bn | 1.26k | -- | 4.35 | -- | 5.00 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 3.19bn | 64.00 | -- | 4.86 | -- | 437.60 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | -- | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Ideaya Biosciences Inc | 15.50m | -128.89m | 3.20bn | 124.00 | -- | -- | -- | 206.15 | -2.00 | -2.00 | 0.2416 | -- | -- | -- | -- | 125,032.30 | -- | -19.17 | -- | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | -- | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.26bn | 18.00k | -- | 1.86 | 35.05 | 1.05 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.28bn | 251.00 | -- | 3.53 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
Data as of May 08 2024. Currency figures normalised to Immunocore Holdings PLC's reporting currency: US Dollar USD
49.27%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Dec 2023 | 6.10m | 12.24% |
| Wellington Management Co. LLPas of 31 Jan 2024 | 5.50m | 11.04% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.94m | 5.91% |
| Rock Springs Capital Management LPas of 31 Dec 2023 | 2.66m | 5.34% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.65m | 3.32% |
| Baker Bros. Advisors LPas of 30 Jan 2024 | 1.52m | 3.04% |
| Paradigm BioCapital Advisors LPas of 31 Dec 2023 | 1.45m | 2.92% |
| Bellevue Asset Management AGas of 31 Dec 2023 | 976.05k | 1.96% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 877.58k | 1.76% |
| Fiera Capital Corp. (Investment Management)as of 31 Mar 2024 | 866.41k | 1.74% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
